Page 80 - Read Online

to activate the “type 1” inflammatory response can be Award to NIH R01CA125244 (Soto H), a UCLA Scholars in
implemented. Enhancing the endogenous immune Translational Medicine Program Award (Yang I), and the
response by deactivating the ensuing chronic STOP CANCER Jason Dessel Memorial Seed Grant (Yang I).
inflammatory tumor microenvironment might provoke
an immune response potent enough to activate and REFERENCES
mobilize endogenous CTL and NK cells to eliminate
the threat posed by high-grade cancerous masses. 1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y,
Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical
report: Primary brain and central nervous system tumors
CONCLUSION diagnosed in the United States in 2006-2010. Neuro Oncol
2013;15 Suppl 2:ii1-56.
It has long been held that tumor cells outwit the 2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,
host’s defenses by altering their own cellular signaling Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U,
Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A,
pathways. The pathway exploited to achieve malignancy Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO;
may be a combination of unique derivations. Gliomas European Organisation for Research and Treatment of Cancer
are known to exhibit compensatory activity in that Brain Tumor and Radiotherapy Groups; National Cancer Institute
when supplied with selective pressure from one of Canada Clinical Trials Group. Radiotherapy plus concomitant
and adjuvant temozolomide for glioblastoma. N Engl J Med
treatment, they readily adapt with other mutations to 2005;352:987-96.
survive. Other mounting evidence now suggests that 3. Hansson GK. Inflammation, atherosclerosis, and coronary artery
some of the pathways exploited by cancer cells adopt a disease. N Engl J Med 2005;352:1685-95.
more malignant phenotype and are simply responses to 4. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors
for ischemic stroke. Stroke 2003;34:2518-32.
the stimuli created by the rapidly dividing tumor cells 5. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s
rather than novel re-circuited pathways exploited by disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol
neoplastic cells for growth. One of the crucial responses 2006;3:390-407.
facilitating and nurturing cancerous transformation 6. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid
arthritis. Nat Rev Immunol 2007;7:429-42.
is inflammation. A chronically active inflammatory 7. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites,
microenvironment provides the developing cancerous apoptotic neurons, and reduced inflammation in cortical multiple
mass with proliferative and mutational factors sclerosis lesions. Ann Neurol 2001;50:389-400.
necessary to realize “self-sufficiency”. It is evident that 8. Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N,
Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P,
some tumors can bypass this “nurturing stage” as might Michel FB. Eosinophilic inflammation in asthma. N Engl J Med
be expected with primary GBM. Regardless, once this 1990;323:1033-9.
“self-sufficiency” is realized, the tumor is able to survive 9. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM,
outside of the cancer stem cell niche. Empowered with Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE,
Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L,
constant proliferative cues the tumor mass divides Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J,
uncontrolled. The increased proliferation results in Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W,
necrosis and the resultant environment is skewed more Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D,
strongly towards the Th2 inflammatory response. Thus, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation
and alzheimer’s disease. Neurobiol Aging 2000;21:383-421.
for high-grade gliomas a higher Th2/Th1 cytokine ratio 10. Dantzer R. Depression and inflammation: an intricate relationship.
supports the production of other immunosuppressive Biol Psychiatry 2012;71:4-5.
factors. To mount a successful cytotoxic anti-tumor 11. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The
response, it is crucial to restore a balanced Th2/Th1 association between fatigue and inflammatory marker levels
in cancer patients: a quantitative review. Brain Behav Immun
cytokine ratio of 1:1 or less. This should decrease the 2007;21:413-27.
proliferative rate of the tumor mass as well, since it 12. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in
is the Th2 response that ultimately works with the neuropathic pain. Brain Res Rev 2006;51:240-64.
tumor cell to drive the angiogenic response. Ultimately, 13. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?
Lancet 2001;357:539-45.
successful brain tumor immunotherapy should leave 14. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related
patients with intact immunosurveillance function and inflammation. Nature 2008;454:436-44.
the ability to enact a cell-mediated response in the 15. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD,
event of recurrence. Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M,
O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S,
Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN,
ACKNOWLEDGMENTS Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW,
Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas
Supported in part by NIH R01CA125244 (Kruse CA, Research Network. Integrated genomic analysis identifies clinically
Liau LM), R01CA154256 (Kruse CA), R01 CA121258 relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
(Kasahara N, Kruse CA), the Joan S. Holmes Memorial 16. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor
Research Fund (Kruse CA), NIH/NCATS UCLA CTSI Grant promoter in cancer induction. Semin Cancer Biol 2004;14:433-9.
Number UL1TR000124 (Liau LM), a NIH Minority Supplement 17. Wager-Smith K, Markou A. Depression: A repair response to

Neuroimmunol Neuroinflammation | Volume 1 | Issue 2 | September 2014 73